AHK-Cu vs GHK-Cu: Two Different Copper Peptides, One Constant Mix-Up

One amino acid apart, and not interchangeable

Both molecules are tripeptides: three amino acids in a chain, holding a copper ion. Read the names slowly and the difference is right there in the first letter.

• GHK-Cu is the glycyl-L-histidyl-L-lysine copper complex. Glycine, histidine, lysine. On a cosmetic ingredient list it appears under its INCI name, Copper Tripeptide-1. It was first described in research published in 1973 by Dr Loren Pickart, who went on to publish 46 papers on it across the following decades. He died in 2023.
• AHK-Cu is the alanyl-histidyl-lysine copper complex. Alanine, histidine, lysine. Same second and third residue, different first one.

That is the whole structural story: swap glycine for alanine at position one. It sounds trivial, and in peptide chemistry it is not. Sequence is identity. Change a residue and you have a different compound, with its own solubility, its own behaviour in a formula, and (this is the part that matters for shoppers) its own separate body of published research. Being different does not make either one stronger or weaker. It makes them non-substitutable when you are reading a citation.

The confusion is easy to forgive. Both are copper peptides. Both are tripeptides. Both contain histidine and lysine, the pair that does most of the copper binding. Marketing then flattens all of it into one phrase, "copper peptides", and the phrase gets used as if it named a single ingredient. It does not. It names a family.

AHK-Cu vs GHK-Cu, side by side

The honest comparison, with the evidence column kept as narrow as the actual studies were:

The hair mix-up, and where it started

You have read the sentence a hundred times: "studies show copper peptides stimulate hair follicles." Follow the footnote and it very often lands on one 2007 paper by Pyo and colleagues, which looked at a copper peptide and hair follicle cells in vitro. That paper studied AHK-Cu, a related copper peptide, not GHK-Cu. And it was cell culture: follicle-derived cells in a controlled dish, measured for growth-related activity.

Two things then happen. First, the "in vitro" qualifier falls off in the retelling, and a dish becomes a scalp. Second, the peptide name gets swapped for whichever copper peptide the page is selling. The citation survives the journey; the molecule does not.

Why does cell culture deserve the asterisk? Because a dish has no blood supply, no immune system, no sebum, no stratum corneum to cross, and no hormones driving pattern hair loss. Cells in culture are how you decide a molecule is worth a human trial. They are not how you decide it works on a person. Plenty of ingredients look impressive in vitro and go nowhere in people, which is exactly why the human column stays empty until someone funds the study.

The demand is real, to be clear. In the 357 Reddit posts we analyzed for our copper peptide community report, 19.3% mention hair or scalp. People are asking. That is precisely why the answer should be accurate rather than convenient.

For context on how copper peptides get compared to the hair ingredient most people already know, we wrote that up separately in copper peptides vs minoxidil. And if you want a sense of what a human hair trial even looks like: a 2015 trial by Panahi and colleagues (PMID 25842469) found rosemary oil matched 2% minoxidil at six months. That is a completely different ingredient, not a copper peptide, and it is included here only to show the difference between a trial in people and a measurement in a dish.

What the evidence actually supports

GHK-Cu has the longer paper trail, and it is worth being precise about what that trail contains. The classic finding is Maquart and colleagues in 1988: GHK-Cu raised collagen synthesis in fibroblast culture. In vitro again. Pickart's 2018 review (PMID 29986520) collects the reported actions and gene-expression data across the literature. Broad, cited constantly, and largely preclinical.

Then there is the result almost nobody quotes. In 1992, a randomized trial in 86 patients tested a copper peptide cream for venous ulcers, and it did not beat placebo (PMID 1495150). A negative result, in humans, in the literature. We index it alongside everything else, because a research library that only keeps the wins is not a library.

Zoom out and the shape of the field is clear. Our GHK-Cu Research Library indexes 60 studies from 1977 to 2026, and only 7 of the 60 are human studies. Fifty-three of them are cell, animal, or mechanistic work. That ratio is the single most useful number in this entire category, and it applies to both peptides on this page.

The honest limit on hair

Stated plainly, because it matters more than anything else here: for hair specifically, evidence for topical copper peptides in humans is thin. Most of what gets cited is cell-culture work, or multi-ingredient formulas where the peptide sits alongside several other actives and cannot be isolated from them. Anyone with progressing hair loss should see a dermatologist, who can look at the actual cause. Cosmetics support appearance. They are not a substitute for that visit.

If you are researching the topic anyway and want realistic expectations rather than promises, our copper peptides for hair results timeline lays out what people actually report and over what period, with the same caveats attached.

Reading an ingredient list

Once you know the two names, the label does the work for you:

• Copper Tripeptide-1 means GHK-Cu. That is the INCI name, so it is the phrase you will see in the ingredient list of a compliant cosmetic. AHK-Cu does not share it.
• AHK-Cu is usually spelled out. Because it does not carry the Copper Tripeptide-1 name, it tends to appear as AHK-Cu itself, or under a supplier's trade name. If a hair product markets "copper peptides" without naming which one, that is a question worth asking the brand.
• A bulk listing is not a finished product. A lot of top AHK-Cu search results are raw-material and research-chemical suppliers. Raw peptide powder sold by the gram is not a formulated cosmetic, and it comes with none of the stability, pH, or preservation work a finished formula requires.
• Percentage beats vocabulary. Of the 16 most-searched copper peptide serums in our GHK-Cu concentration by brand table, only 8 publish an exact GHK-Cu percentage, and the disclosed doses run from 0.10% to 3%. A named peptide plus a stated percentage tells you more than any adjective on the front of the bottle.

Why we claim skin, not hair

Our position follows directly from the paragraphs above. MAXXING Glow is a GHK-Cu topical serum, so the peptide in it is the glycyl-histidyl-lysine complex listed as Copper Tripeptide-1. It is a cosmetic, formulated to support the appearance of skin. That is what we say about it, and it is where the GHK-Cu literature actually sits, in skin and fibroblast work.

What we do not do is borrow the hair follicle data. That research was run on AHK-Cu, in cell culture. Pointing at it to sell a face serum would mean stacking two errors on top of each other: the wrong molecule, and a dish standing in for a person. Plenty of pages in this category make exactly that move, usually without meaning to, because the citation has been passed along so many times that the original peptide name has fallen off it.

None of this is a knock on AHK-Cu. It is a legitimate peptide with its own early-stage research, and if the human studies get funded, that will be genuinely useful to know. It simply is not the peptide in a GHK-Cu serum, and its cell-culture results are not evidence for one. If you want the full topical picture on the peptide we do formulate with, including the routine questions and the honest limits, start at our GHK-Cu hub.

The short version of our standard: we would rather publish the distinction that costs us a hair-growth headline than keep a claim that does not survive a look at the footnote.

Frequently asked questions